US 12,263,170 B2
Systems and methods for treating cancer
Timothy G. Whitsett, Jr., Phoenix, AZ (US); and Landon J. Inge, Phoenix, AZ (US)
Assigned to Dignity Health, San Francisco, CA (US); and The Translational Genomics Research Institute, Phoenix, AZ (US)
Filed by Dignity Health, Phoenix, AZ (US); and The Translational Genomics Research Institute, Phoenix, AZ (US)
Filed on Apr. 2, 2021, as Appl. No. 17/220,977.
Application 17/220,977 is a continuation of application No. 16/565,605, filed on Sep. 10, 2019, granted, now 10,993,946.
Application 16/565,605 is a continuation of application No. 15/740,546, granted, now 10,449,197, issued on Oct. 22, 2019, previously published as PCT/US2015/062785, filed on Nov. 25, 2015.
Claims priority of provisional application 62/187,442, filed on Jul. 1, 2015.
Prior Publication US 2021/0251998 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 31/282 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2019.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/282 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2300/00 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating adenocarcinoma in a subject, the method comprising the steps of (a) identifying at least a portion of adenocarcinoma cells in the subject as deficient in liver kinase B1 (LKB1) and (b) administering a therapeutically effective amount of a Wee1 kinase inhibitor to the subject, wherein the adenocarcinoma in the subject is deficient in liver kinase B1 (LKB1).